235 related articles for article (PubMed ID: 16857803)
1. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
Kwak EL; Jankowski J; Thayer SP; Lauwers GY; Brannigan BW; Harris PL; Okimoto RA; Haserlat SM; Driscoll DR; Ferry D; Muir B; Settleman J; Fuchs CS; Kulke MH; Ryan DP; Clark JW; Sgroi DC; Haber DA; Bell DW
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4283-7. PubMed ID: 16857803
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
Pao W; Miller VA; Politi KA; Riely GJ; Somwar R; Zakowski MF; Kris MG; Varmus H
PLoS Med; 2005 Mar; 2(3):e73. PubMed ID: 15737014
[TBL] [Abstract][Full Text] [Related]
3. Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas.
PĆ¼hringer-Oppermann FA; Stein HJ; Sarbia M
Dis Esophagus; 2007; 20(1):9-11. PubMed ID: 17227303
[TBL] [Abstract][Full Text] [Related]
4. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
5. Detection of epidermal growth factor receptor mutation in the peripheral blood of patients with esophageal carcinoma to guide epidermal growth factor receptor-tyrosine kinase inhibitor treatment.
Xu Y; Xie Z; Lu H
J Cancer Res Ther; 2018 Jan; 14(1):103-105. PubMed ID: 29516969
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
7. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
8. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
10. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
[TBL] [Abstract][Full Text] [Related]
11. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Taron M; Ichinose Y; Rosell R; Mok T; Massuti B; Zamora L; Mate JL; Manegold C; Ono M; Queralt C; Jahan T; Sanchez JJ; Sanchez-Ronco M; Hsue V; Jablons D; Sanchez JM; Moran T
Clin Cancer Res; 2005 Aug; 11(16):5878-85. PubMed ID: 16115929
[TBL] [Abstract][Full Text] [Related]
12. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
13. Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.
Wang WP; Wang KN; Gao Q; Chen LQ
World J Surg Oncol; 2012 Jan; 10():14. PubMed ID: 22252115
[TBL] [Abstract][Full Text] [Related]
14. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases.
Schneider PM; Casson AG; Levin B; Garewal HS; Hoelscher AH; Becker K; Dittler HJ; Cleary KR; Troster M; Siewert JR; Roth JA
J Thorac Cardiovasc Surg; 1996 Feb; 111(2):323-31; discussion 331-3. PubMed ID: 8583805
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor mutations as a prognostic factor in Korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors.
Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Chemotherapy; 2011; 57(2):108-14. PubMed ID: 21411993
[TBL] [Abstract][Full Text] [Related]
16. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
[TBL] [Abstract][Full Text] [Related]
17. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Bean J; Riely GJ; Balak M; Marks JL; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2008 Nov; 14(22):7519-25. PubMed ID: 19010870
[TBL] [Abstract][Full Text] [Related]
19. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
[TBL] [Abstract][Full Text] [Related]
20. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas.
al-Kasspooles M; Moore JH; Orringer MB; Beer DG
Int J Cancer; 1993 May; 54(2):213-9. PubMed ID: 8098013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]